MHRA Fast-Tracks Approval of New XGEVA Formulation via International Recognition Procedure

The UK's MHRA has authorized a new formulation of XGEVA (denosumab) through the new International Recognition Procedure (IRP) in just 30 days. This faster approval process, launched in January 2024, aims to expedite access to new medicines for UK patients by incorporating assessments from trusted regulatory partners worldwide. Denosumab, used to prevent serious bone complications and treat giant cell tumor of bone, is now available as a more convenient prefilled syringe.

The following article originally appeared in gov.uk.

A new formulation for XGEVA (denosumab), a treatment used in adults to prevent serious bone-related complications caused by bone metastasis and to treat giant cell tumour of bone in adults and adolescents, is the first product to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) via the new International Recognition Procedure (IRP). The product was authorised in 30 days, providing UK patients with earlier access to this treatment thanks to international recognition.

Launched in January this year, the IRP allows the MHRA to accelerate the assessment of new medicines by taking into account the expertise and decision-making of trusted regulatory partners in the authorisation process. As a result, medicines that have been approved in other countries with stringent regulators will get to UK patients without delay, resulting in a more rapid, efficient, and cost-effective process for life sciences companies.

Denosumab (XGEVA) was authorised on 29 February 2024 as a 120 mg solution for injection in a prefilled syringe. This means that UK patients will have access to a more convenient option compared to the current vial presentation, as denosumab will now be provided at the same dose but in a higher concentration, already loaded in a syringe. This simplifies the administration process, reduces the volume of liquid injected, and lowers the risk of dosing errors.

Patients and caregivers who have been trained in injection techniques by a healthcare professional can now administer the product. The first self-administration should be supervised by a healthcare professional.

The product was initially reviewed by the European Medicines Agency (EMA) and received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) on 25 January 2024. The MHRA considered the assessment made by the European regulator as part of its own review, facilitating a rapid approval process.

IRP is open to applicants that have already received an authorisation for the same product from one of MHRA’s specified trusted regulators. These are the regulatory authorities from Australia, Canada, the European Union, Japan, Switzerland, Singapore and the United States.

As a sovereign regulator, the MHRA retains ultimate authority to accept or reject applications submitted under the IRP, ensuring that all products meet safety, quality and effectiveness standards to be licensed in the UK.

Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access, said:

We are focused on providing UK patients rapid access to safe and effective medical treatments.

I’m very pleased to announce that we have granted the first approval through IRP in 30 days, demonstrating that this new process for bringing new medicines to UK patients is well under way.

We’re assured that the appropriate regulatory standards for the approval of this medicine have been met. As with all products, we will keep its safety under close review.

Health Minister Andrew Stephenson said:

NHS patients should have access to the newest, most effective medicines and treatments without delay.

This new international agreement allows treatments to be approved more quickly by drawing on expertise from partners across the world, reducing bureaucracy and sharing resources so patients can benefit as soon as possible.

XGEVA being approved quicker than usual is testament to this innovative approach.

How the medicine works

The active ingredient in XGEVA, denosumab, is a protein that works to slow down bone destruction caused by cancer spreading to the bone (bone metastasis) or by giant cell tumour of bone.

Evidence base

This approval is supported by acceptable evidence of the quality of the new formulation of denosumab in a prefilled syringe, including manufacturing, release testing and shelf-life. Since the new formulation will be used to treat the same conditions as the existing medicine at the same dose, no new clinical studies needed to be conducted.

Side effects

The most common side effects of the medicine (which may affect more than 1 in 10 people) include bone, joint and/or muscle pain which is sometimes severe, shortness of breath, diarrhoea, and low calcium levels in the blood.

As with any medicine, the MHRA will keep the safety and effectiveness of XGEVA under close review. Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme, either through the website or by searching the Google Play or Apple App stores for MHRA Yellow Card.

For more, please find the original story source here.